Prosecution Insights
Last updated: August 18, 2026
Application No. 18/431,725

TREATMENT OF SEPSIS AND SEPTIC SHOCK

Final Rejection §112
Filed
Feb 02, 2024
Priority
Apr 20, 2018 — EU 18168436.6 +2 more
Examiner
AZPURU, CARLOS A
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Combioxin SA
OA Round
3 (Final)
84%
Grant Probability
Favorable
4-5
OA Rounds
1m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1082 granted / 1291 resolved
+23.8% vs TC avg
Moderate +11% lift
Without
With
+10.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
37 currently pending
Career history
1316
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
24.5%
-15.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
30.4%
-9.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1291 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant has filed an amendment on 06/03/2026 which contains independent claims of differing scope. Calls were placed to Donald V. Scaltrito on 06/30/2026 and 07/06/2026, but no response was returned. .Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 16-26 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 16 and 18 have been amended to contain the phrase : PNG media_image1.png 51 644 media_image1.png Greyscale The is no support in the original specification for this phrase and it is considered new matter. Claims 19 and 20 have been amended to contain the phrase: PNG media_image2.png 52 592 media_image2.png Greyscale The is no support in the original specification for this phrase and it is considered new matter. Claims 21-26 have been amended to contain the phrase: PNG media_image3.png 69 613 media_image3.png Greyscale There is no support in the original specification for thus phrase, and it is considered new matter. Conclusion Claims 1-3, 5, 7,and 9-15 are allowed. Applicant is advised to also change the dependency of claims 16, 19, 20 and 21 so as to depend on claim 1 so that the scope of the claims is the same. Applicant is further advised to amend the “Description of the Figures” to “Brief Description of the Drawings” Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARLOS A AZPURU whose telephone number is (571)272-0588. The examiner can normally be reached 9 am- 3 pm, 4 pm-8pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue X Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARLOS A AZPURU/Primary Examiner, Art Unit 1617 caz
Read full office action

Prosecution Timeline

Feb 02, 2024
Application Filed
Nov 12, 2025
Non-Final Rejection mailed — §112
Feb 11, 2026
Response Filed
Mar 03, 2026
Non-Final Rejection mailed — §112
Jun 03, 2026
Response Filed
Jul 08, 2026
Final Rejection mailed — §112
Aug 17, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702640
DRUG IMPLANTS CONTAINING ENZALUTAMIDE AND METHODS OF USE THEREOF
3y 3m to grant Granted Aug 11, 2026
Patent 12702646
MICROSPHERE FORMULATIONS COMPRISING NALMEFENE ANDMETHODS FOR MAKING AND USING THE SAME
2y 10m to grant Granted Aug 11, 2026
Patent 12685758
COMPOSITIONS AND METHODS FOR INHIBITING THE BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES
2y 11m to grant Granted Jul 21, 2026
Patent 12678448
POLYMERIC CARRIERS FOR DELIVERY OF THERAPEUTIC AGENTS
3y 6m to grant Granted Jul 14, 2026
Patent 12678536
BIOCOMPATIBLE POLYMER, BIOCOMPATIBLE COMPOSITIONS, SOL OR GEL, AND INJECTABLE COMPOSITION
3y 4m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.6%)
2y 7m (~1m remaining)
Median Time to Grant
High
PTA Risk
Based on 1291 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month